Table 2.
Drugs currently in clinical trials for the treatment of various etiologies of hepatic fibrosis according to ClinicalTrials.gov
|
Drug name
|
Mechanism of action
|
Condition(s)
|
Clinical phase
|
Study/Identifier
|
| Candesartan + Ramipril | Angiotensin II receptor Antagonist, ACE inhibitor | HCV | 3 | NCT03770936 |
| Pirfenidone | Anti-inflammatory + Antifibrotic | Multiple | 2 | [PROMETEO] NCT04099407 |
| BMS-986036, Pegbelfermin | PEG-FGF21Analog | NASH F3 | 2 | [FALCON 1] NCT03486899 |
| NASH + Compensated, Cirrhosis | 2 | [FALCON 2] NCT03486912 | ||
| Aldafermin (NGM282) | FGF19 Analog | NASH | 2 | NCT02443116 |
| CC-90001 | JNK inhibitor | NASH F3/F4 | 2 | NCT04048876 |
| Entecavir | Reverse transcriptase inhibitor | HBV | 4 | NCT02849132 |
| Entecavir + Fuzheng Huaya + TCM granule | Reverse transcriptase inhibitor + Traditional Chinese medicine | HBV | 4 | NCT02241616 |
| Tropifexor + Licoglifozin | FXR agonist + SGLT 1 and 2 inhibitor | NASH F2/F3 | 2 | [ELIVATE] NCT04065841 |
| Tropifexor + Cenicriviroc | FXR agonist + CCR2-CCR5 antagonist | NASH F2/F3 | 2 | [TANDEM] NCT03517540 |
| Nitazoxanide | Anti-protazoal | NASH F2/F3 | 2 | NCT03656068 |
| Mesenchymal stem cells | Umbilical cord mesenchymal stem cells | HBV + Decompensated cirrhosis | 2 | NCT03945487 |
| GXHPC1 | Adipose-derived stem cells | Cirrhosis of multiple etiologies | 2 | NCT04088058 |
| G-CSF | Granulocyte colony stimulating factor | Decompensated cirrhosis of multiple etiologies | 2/3 | NCT03911037 |
| Mesenchymal stem cells | Autologous bone marrow mesenchymal SCs | Cirrhosis of multiple etiologies | 2 | NCT03626090 |
| ADR-001 | Adipose-derived stem cells | HCV or NASH Cirrhosis | 2 | NCT03254758 |
| CD 34 + MSCs | Autologous hematopoietic and mesenchymal SCs | Cirrhosis of multiple etiologies | 4 | NCT04243681 |
| Simvastatin | HMG-CoA Reductase Inhibitor | Cirrhosis of multiple etiologies | 2 | NCT02968810 |
| ORMD-0801 | Oral insulin formulation | NASH + Type 2 Diabetes | 2 | NCT02653300 |
| Atorvastatin | HMG-CoA reductase inhibitor | Cirrhosis of multiple etiologies | 4 | [STATLiver] NCT04072601 |
| Aldafermin (NGM282) | FGF19 analog | NASH F2/F3; NASH + Compensated cirrhosis | 2; 2 | [ALPINE 2/3] NCT03912532; [ALPINE 4] NCT04210245 |
| Obeticholic acid | FXR agonist | PBC + Hepatic impairment | 4 | NCT03633227 |
| Stem cell | Autologous bone marrow mononuclear stem cells | Liver cirrhosis + Biliary atresia | 2 | NCT03468699 |
| VK2809 | Thyroid receptor agonist | NASH | 2 | [VOYAGE] NCT04173065 |
| Spironolactone + Carvedilol | Aldosterone antagonist + Beta receptor blocker | Compensated cirrhosis | 4 | NCT02907749 |
| Cenicriviroc | CCR2-CCR5 antagonist | NASH + Completion of CENTAUR and AURORA Study | 2 | NCT03059446 |
| Selonsertib + Firsocostat + Cilofexor + Fenofibrate + Vascepa® | ASK 1 inhibitor + ACC inhibitor + FXR agonist + Anti-lipid + Anti-lipid | NAFLD, NASH | 2 | NCT02781584 |
| Erlotinib | Tyrosine kinase inhibitor | Fibrosis, Cirrhosis | 1/2 | NCT02273362 |
| Saroglitizar | PPAR agonist | NAFLD, NASH | 2 | NCT03061721 |
ACC: Acetyl-CoA carboxylase; ASK: Apoptosis signal-regulating kinase 1; CCR: Chemokine receptor; FXR: Farnesoid X receptor; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HMG-CoA: Hydroxymethylglutaryl coenzyme A; JNK: C-Jun N-terminal kinase; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; PBC: Primary biliary cirrhosis; PEG-FGF21: PEGylated human fibroblast growth factor 21; PPAR: Peroxisome proliferator-activated receptor; SGLT-1: Sodium-glucose transport protein 1; SGLT-2: Sodium-glucose transport protein 2; TCM: Traditional Chinese Medicine.